CD8A and neoplasm: By combining an anti-PD-1 antibody to block immunosuppressive signaling on CD8+ T cells with PCLX-001 to reduce PD-L1 membrane localization on tumor cells, this approach maximizes the disruption of PD-1/PD-L1-mediated immune evasion.